IMMUNEONCO-B (01541) has announced that on September 11, 2026, the company repurchased 55,200 of its shares for a total consideration of HK$177,600.
The buyback transaction was disclosed in an official filing, reflecting the company's ongoing capital management strategy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.